Electrohypersensitivity (EHS)
Electrohypersensitivity (EHS)
Electrohypersensitivity is a recognized condition where individuals experience a wide range of adverse symptoms in response to man-made electromagnetic fields (EMFs) at levels far below established safety limits. Once dismissed, it is now gaining legal and medical recognition as a legitimate, disabling neuropathological disorder.
The condition is characterized by a diverse symptomatic profile, suggesting a multi-systemic biological dysregulation rather than a localized issue.
EHS presents a diverse range of complaints, with neurological and systemic symptoms being the most prominent.
Man-Made EMF Exposure
(Pulsed, Polarized)
VGCC Activation
(Voltage-Gated Calcium Channels)
Oxidative Stress
(Increased ROS Production)
Low-Grade Neuroinflammation
Activation of microglia, astrocytes, and mast cells in the central nervous system.
Blood-Brain Barrier (BBB) Disruption
Compromised barrier allows inflammatory cells to enter the brain.
Specific variations in detoxification pathway genes (e.g., GSTT1, GSTM1) can increase EHS risk by nearly 10-fold.
Elevated levels of Histamine (2-10x higher) and Heat Shock Proteins (HSP) indicate chronic, low-grade inflammation.
Increased Protein S100B and Nitrotyrosine in the blood confirm a compromised blood-brain barrier.
A notable decrease in the excretion of 6-hydroxymelatonin sulfate is found in ~90% of EHS cases, impacting sleep and antioxidant defense.
Anti-myelin autoantibodies are detected in ~15% of cases, suggesting the immune system may attack nerve sheathings.
EMF exposure can alter HRV, indicating a physiological stress response and a disturbed circadian rhythm.
The cornerstone of EHS management is avoidance. Reducing exposure to man-made EMFs is the most effective strategy for alleviating symptoms. This involves adopting "Safe Tech" practices.
Patient surveys show dietary changes and supplements are perceived as highly effective complementary treatments.
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
WhatsApp us